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Recent changes in the Fungal Code of Nomenclature and developments in molecular phylogeny are about to lead to dramatic
changes in the naming of medically important molds and yeasts. In this article, we present a widely supported and simple pro-
posal to prevent unnecessary nomenclatural instability.
ONE FUNGUS, ONE NAME
Until recently, polymorphic higher fungi (Dikarya) were allowedto carry multiple names describing sexual (teleomorph) and
various asexual (anamorph) stages of their life cycles. These stages
could develop independently from each other, and their genetic
relationship was often difficult to establish. Today, with the wide
application of molecular methods, this problem has largely been
solved. With the introduction of molecular genetic approaches,
the dual naming system is no longer necessary. Two international
expert symposia recently held in Amsterdam, The Netherlands,
have been devoted to the fate of dual naming in fungi: One Fun-
gus  One Name symposium on 19 and 20 April 2011 and One
FungusWhich Name symposium on 12 and 13 April 2012. The
resulting Amsterdam Declaration on Fungal Nomenclature (1)
requested the abolition of Article 59 of the Code of Botanical No-
menclature, the provision that sanctioned multiple names for the
same fungus. Under the new Code of Nomenclature of Algae,
Fungi and Plants, from 1 January 2013, this system is no longer
permitted. One of the consequences of the declaration is that the
criteria for naming fungi have changed entirely.
The dual naming system had been useful during the age of the
microscope. Today, the main criteria for classification have moved
from phenotype to genotype. Analysis of nucleic acid sequence vari-
ation now guides taxonomy and has replaced phenotype with the
history of phylogenetic relationships and, occasionally, sexual com-
patibility. The first phase began after the introduction of PCR in the
late 1980s and resulted in the discovery of new species by concor-
dance of gene genealogies in several pathogenic fungi. This is now
being expanded following the advent of next-generation sequencing,
which is discovering genetically distinct populations that deserve spe-
cies status. The newly discovered species are genealogically distinct
but cryptic in the sense that they were not suspected frommorpho-
logical phenotype—although after they are recognized, distinguish-
ing phenotypesmay be discovered later on. In addition, taxonomyof
environmental fungi is developing at a very rapid pace, which has a
profound impact onnomenclature of opportunistic fungi. Anatomic
morphological categories, such as coelomycetes or hyphomycetes,
have become redundant, which implies that all mycological text-
books have become obsolete. Diagnostic laboratories will have to
change the type and interpretation of data used to identify fungi. The
changes will hopefully contribute to nomenclatural stability in the
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future, but it is obvious that thiswill not be achievedbefore the endof
a transition phase. Although the shift in identification can be viewed
as simply a change in technique frommicroscopy to DNA sequence
analysis, itmust also be viewed as amajor intellectual shift to a system
based on evolution as inferred from comparison of genotypes.
Coincidently with this process, a significant expansion of the
number of etiologic agents of disease is noticed. In the literature, it
is often stated that (i) this growth is especially due to the increasing
population of immunocompromised patients. A more pertinent
cause, however, is (ii) the development of our knowledge, driven
by easy access to sequencing technology. The advent of population
genomics, which increases the sampled diversity by as many as 4
orders ofmagnitude, can only increase this trend. A further source
of new clinical species to be recognized in diagnostic laboratories
is the fact that (iii) also sterile or nonculturable fungi can now be
classified according to sequence analysis of PCR-generated ampli-
cons. The expansion of the number of clinically relevant fungi is
clearly demonstrated in the Atlas of Clinical Fungi of which the
first edition (2) contained 320 species, while the 2013 edition of
the same book (3) counts a staggering 560 species, and the number
of species is still growing at the same pace.
When only a single name should be used for these fungi, most
ofwhich bear several names at present, the question iswhich name
has priority?One of the principles of nomenclature is to choose (i)
the oldest name, either anamorph or teleomorph, which is also
mostly the most widely applied name. The new code has the sec-
ond rule that if both anamorph and teleomorph names have been
widely used, (ii) the teleomorph name is to bemaintained unless a
formal application in favor of the anamorph name has beenmade.
Both choices are dependent on (iii) the size of the genus and its
rank in the taxonomic hierarchy.
CHANGES AT THE GENUS LEVEL AND ABOVE
Starting with item iii, genus concepts are related to the amount
and diversity of available biological material. Nucleic acid varia-
tion has provided a means of ensuring that genera are monophy-
letic, which is a leading principle of modern taxonomy. Species
differing at the ordinal or even family level are no longer accepted
as members of a single genus. Hence, orders and sometimes fam-
ilies are taxonomically relevant entities. The advantage of the phy-
logenetic approach is that close relatives come together even if
they are morphologically quite different; this may be useful for
predictions of pathogenicity or antifungal susceptibility. Con-
versely, distant relationships are expected to predict large differ-
ences in clinically relevant parameters. Until today, most clinical
fungi had been grouped in anamorphic form genera based on
phenotype that do not necessarily represent phylogenetic related-
ness. For example, non-albicans Candida species comprise a ran-
dom mixture of species that have been grouped together only
because they are morphologically indistinguishable and physio-
logically similar, but some of them are as distant from each other
as humans are from frogs. Applying names that acknowledge this
diversity would be logical and medically meaningful. Candida al-
bicans and Candida glabrata are evolutionary distant species with
different antifungal susceptibilities (4). Penicillium marneffei is
unrelated to most of the saprobic Penicillium species, but it be-
longs to a group of penicillium-like species classified in the genus
Talaromyces that possess similar virulence factors. Therefore, re-
classification of P. marneffei in Talaromyces (5) is useful for the
medicalmycologist. Similar reasoning can be applied to categories
higher up in the fungal system. Although the Zygomycota appears
not to be monophyletic, there has been reluctance to abandon the
name, but as the diseases caused by themain groups composing it,
the Mucoromycotina and Entomophthoromycotina, are funda-
mentally different (6), their separation would be a step forward.
The novel approach using phylogeny as amain criterion enhances
information content of the taxonomy hierarchy.
The above is valid on the assumption that the “real” phyloge-
netic tree of the fungal kingdom is known. However, it should be
realized that only a minor fraction of the existing fungal diversity
has been described thus far. Large numbers of novel species are
continuously being discovered due to the exploration of new hab-
itats. Themain cause of generic instability is material driven; phy-
logenetic trees are highly sensitive to taxon sampling effects (Fig.
1), and this situation will remain for many decades to come. De-
scription of species on the basis of single sequences from metag-
enomic data will further complicate the taxonomic system (7).
The basis of a genus or of any higher rank in the taxonomic hierarchy
is amonophyletic branch of an underlying phylogenetic tree, replac-
ingphenotypic techniques. Fungimayappear tobelong tootherphy-
logenetic groups than hypothesized earlier.
The clade approach for naming species, genera, and above has
fundamental shortcomings, because of the comparative nature of
data and also because no delimitation criterion exists. Determina-
tion of all higher taxonomic ranks when they are defined exclu-
sively by sequence data is inherently arbitrary and therefore un-
stable, leading to numerous transfers of species from one genus
to the next. Phylogeny deepens our understanding of the fungal
kingdom, but phylogenetic trees are just an approximation of the
truth. During the last 10 years, more name changes have been
proposed for medical fungi than in the previous 70 years; exam-
ples can be found in Table 1. Many clades in a tree can be statisti-
cally supported, but what is the level of diversity to recognize a
genus? At present, Aspergillus contains about 290 species, while
genera in the Scedosporium lineage, with comparable levels of bar
coding gaps between neighboring taxa, contain only 1 to 6 species.
If genera become nearly congruent to species, then the genus be-
comes a redundant category.
A profoundly debated example is the anamorph genus Asper-
gillus. The Aspergillus genus was discovered by Micheli in 1753,
based on Aspergillus glaucus. However, the medically important
fungus Aspergillus fumigatus is a member of another phylogenetic
clade in Aspergillus that also bears the teleomorph name Neosar-
torya. In the case of A. fumigatus, which was found to have a
Neosartorya sexual state in 2009 after a concerted effort to generate
ascocarps (8), the anamorph nameA. fumigatus is older andmore
widely used thanN. fumigata. However, theA. fumigatus/N. fumi-
gata clade is phylogenetically remote and phenotypically distinct
from the clade that contains the generic type,A. glaucus (9). There
are two proposals in the literature. One advocates making Asper-
gillus a very large genus covering numerous clades, including
those of A. glaucus and A. fumigatus (9). After careful discussion
among the members, this proposal was chosen by the Interna-
tional Commission of Penicillium and Aspergillus. The other ad-
vocates applying existing teleomorph names to all monophyletic
branches except one, and that clade alone would retain the name
Aspergillus (10).
Both proposals have their pros and cons. In the first case,
Aspergillus would remain the name for all, but as the broad phy-
logeny includes genera such as Phialosimplex and Polypaecilium
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would have to be renamed in Aspergillus. The breadth of pheno-
type embraced by Aspergillus would include fungi that have never
been associated with Aspergillus, but the phylogenetic data sup-
porting this are solid (11), and it should be acknowledged that
aspergilli with deviating morphological features do exist. In the
second case, A. fumigatus would be named Neosartorya fumigata
because Neosartorya species form a distinct monophyletic clade
within the exiting genus Aspergillus. This may be unpleasant for
medical mycologists, but for many other users of the fungal king-
dom, this is good news as Aspergillus would then be used to refer
specifically to Aspergillus species in the subgenus Circumdati.
These include fungi with even more prominent economic value,
for example the Asian food fungus, Aspergillus oryzae, its close
relative, the aflatoxin producer, Aspergillus flavus, and the indus-
trial fermentation workhorse, Aspergillus niger.
In summary, a major source of potential name changes, in
addition to problems of dual nomenclature, is linked to phylogeny
as a leading principle, while phylogenetic trees and taxonomic
hierarchies are still under construction and subject to change
while nature’s diversity is better understood.
CHANGES AT THE SPECIES LEVEL AND BELOW
Species recognition is primarily method driven, i.e., tied to the
method of observation. The shift from recognizing species by ob-
servable phenotype to recognizing them by nucleic acid variation
has resulted in a proliferation in the number of species. In recent
years, more precision has been achieved in molecular methods by
replacing species recognition in single-gene studies by multiple-
gene analysis of lineages and populations, leading to molecularly
defined taxa (sibling or cryptic species; Table 2). This trend will
continue now that whole genomes are becoming available for
large numbers of strains within a single species, as has been shown
with model fungi (12–14).
When this process is clinically relevant, the novel naming sys-
tem should rapidly be adopted. For example, Sporothrix schenckii,
agent of human sporotrichosis, contains a hypervirulent sibling
now known as Sporothrix brasiliensis causing large epidemics in
Brazil (15). In another example, Scedosporium aurantiacum, one
of the novel species recognizedwithin the former umbrella species
Scedosporium apiospermum is significantly less susceptible to cur-
rently used antifungal agents than the original species (16).
Application of more-variable genes to the same fungi will al-
ways lead to discovery ofmore diversity, again as demonstrated by
population genomics. Almost all fungal species that have been
examined show evidence of recombination and, therefore, exhibit
upper and lower bounds to species recognition. The lower bound
has been found using population genomic analysis to identify ge-
netically differentiated populations of interbreeding individuals,
and development of the upper bound has been observed where
species have evolved reinforced barriers tomating in some areas of
sympatry and not others (17). Only in clonal species would these
bounds not apply and entities can be subdivided ad infinitum. In
FIG 1 Diagram of name changes driven by methodical advances and sampling effects: subdivisions, reallocations, and rank inflations.
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practice, many, perhaps most, fungal lineages combine enough
recombination with clonal behavior to be constrained by both
upper and lower species boundaries. There is no gold standard as
a measure of taxonomic diversity at the species level, and thus
optimal barcoding genes are differentially effective between dif-
ferent groups.
Differences between molecular siblings may not always have
clinical relevance. Distinction of cryptic species may then be tax-
onomically valid and scientifically meaningful but remain unde-
tectable in routine laboratory analyses. On a global scale of daily
clinical diagnostics, attempting to detect these species would re-
quire an investment that would not contribute to patient care and
is therefore not recommended until further research provides jus-
tification of these additional efforts. For example,Aspergillus niger
was recently found (18) to contain a molecular sibling, Aspergillus
awamori. Varga et al. (19) explicitly mention that there are no
differences in phenotypic characteristics, such as metabolite pro-
files between the two, and clinical differences between the two
species have yet to be discovered. As difficult as it might be to
distinguish two species, imagine the case of the ubiquitous con-
TABLE 1 Some examples of medically important fungi that have undergone recent multiple changes, with year of publication and reasons for
rearrangement
Original name in medicine Transitional name(s) Current name
Hendersonula toruloidea 1933 Scytalidium hyalinum 1977 (supposed synonymy) Neoscytalidium dimidiatum 2006
(phylogenetic rearrangement)
Scytalidium dimidiatum 1989 (earlier synonym Torula dimidiata 1887)
Nattrassia mangiferae 1989 (supposed identity of coelomycete anamorph)
Fusicoccum dimidiatum (2005) (phylogenetic rearrangement)
Neofusicoccum mangiferae 2006 (phylogenetic rearrangement)
Neoscytalidium hyalinum 2013 (phylogenetic rearrangement)
Trichosporon capitatum 1942 Geotrichum capitatum 1977 (phylogenetic rearrangement) Saprochaete capitata 2004 (phylogenetic
rearrangement of anamorph)
Blastoschizomyces capitatus 1985 (synanamorph genus) Magnusiomyces capitatus 2004
(phylogenetic rearrangement of
teleomorph; priority of either genus
name still to be established)
Blastoschizomyces pseudotrichosporon 1982 (synonymy)
Dipodascus capitatum 1996 (description of teleomorph)
Candida utilis 1952 Hansenula jadinii 1979 (conspecificity with Candida utilis, description of
teleomorph)
Cyberlindnera jadinii 2009
(nomenclatural correction)
Pichia jadinii 1984 (phylogenetic rearrangement)
Lindnera jadinii 2008 (phylogenetic rearrangement)
Allescheria boydii 1922 Pseudallescheria boydii (teleomorph) Scedosporium boydii (consensus chosen
by Scedosporium community, but
Pseudallescheria teleomorph genus
name has been prioritized by
nomenclatural community)
Cephalosporium boydii 1922 Scedosporium boydii (prevalent anamorph; name for third morph neglected)
Dendrostilbella boydii 1922
(anatomic names for a
trimorphic fungus)
TABLE 2 Some taxonomic definitions appropriate for medical mycology that are used in the present paper
Term Taxonomic definition
Species complex A monophyletic clade of species with equivalent clinical relevance
Sibling species Species that share the same, most recent common ancestor
Cryptic species Species recognized by nucleic acid variation that had not been recognized as distinct by morphological phenotypes.
Once recognized, phenotypic characters useful for identification may be discovered in the future.
(Sub)clade/monophyletic group Phylogenetic group consisting of an ancestral species and all its descendants. Clades and subclades can be
recognized at any given taxonomic level. Statistical tests are used to gauge the support for these groups.
Lineage Series of species connected by evolutionary descent, not necessarily representing all known descendants
Cluster/group Terminal series of phylogenetically related species, used when precise relationships are uncertain.
Type Entity defining a taxonomic name and indicated as such in the protologue. Species and below are defined by a
specimen, whereas higher taxonomic entities are defined by the first lower category.
Neotype New specimen in accordance with the protologue in case the original type material is lost.
Epitype Reference specimen accordance with the protologue when the original material is not interpretable.
Protologue Original description and any other representation of a taxonomic entity.
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taminant Cladosporium cladosporioides, which today contains 39
cryptic species (20), 38 of which have never been proven as agents
of human infection.
Neighboring siblings that are identical in patient management
and normally characterized phenotype might in routine diagnos-
tics better be taken together as “complexes.” A “species complex”
of medically important fungi would be considered a cluster of
cryptic species that are clinically identical. This is the current in-
dication of series of closely related Fusarium species (21), and
similar approaches have been adopted for Cladosporium (20) and
elsewhere. The word “complex” has no nomenclatural status
and does not require any name change. Species complexes can
nevertheless be sharply delimited and validated bymolecular data.
Diagnostic markers can be developed for the molecular siblings
and for the species complex. If an author wishes to describe other,
less clearly defined species diversities, terms like “group,” “clus-
ter,” “lineage,” and “clade” are available (Table 2).
In summary, amajor sourceof namechanges at the species level is
increased precision of molecular techniques; this nomenclatural in-
stability is thus largely method driven. The distinguished entities,
evenwhen scientifically correct andmeaningful,maynot alwayshave
clinical relevance, although this significance may perhaps be discov-
ered in the future.
CONCLUSIONS AND PROPOSALS
During the process of naming each fungus, teleomorph and ana-
morph names as well as their synonyms are being considered in a
way that would increase acceptance and stability. Even strict no-
menclatural rules provide a certain degree of liberty. Many of the
classical medical fungi and many of their synonyms were de-
scribed a long time ago, and type material is often lacking or un-
interpretable. The present paper does not argue for one solution
or the other in any of the examples above but simply notes that
there is more than one way to apply one name for one fungus.
Nomenclatural changes of medically important fungi usually take
decades to gain wide acceptance. Any change may be viewed as a
process taking place in the community, rather than as a singular
result of a phylogenetic study. Taxonomy is a dynamic science,
which cannot be muzzled by nomenclatural protocols. Realloca-
tions, rank changes, and generic disarticulations or reunifications
will remain common practice. Theoretically, the taxonomic sys-
tem should reflect the true phylogeny of the fungal kingdom, but
obviously we have not yet reached that stage. Additional data and
techniques improving the system are continually generated and
published. Therefore, itmay bemore prudent towait until a larger
degree of stability and consensus is achieved. Many names of op-
portunistic fungi are published as part of studies on environmen-
tal fungi, where genera might comprise dozens or hundreds of
species. The genus name is linked to its type species, and if this
species appears to be different from all the others, all remaining
names need to be recategorized in another genus. The result is that
the number of name changes can be tremendous—a compelling
reason to be careful with reallocations where scientific support is
still fragmentary.
How should the field of medical mycology treat the new diver-
sity seen in the taxonomy of medically important fungi? At the
genus level, these are reallocations, rank changes, and generic dis-
articulations or reunifications that stem from studies of morema-
terials and from having to choose one name from two or more
current names.Where examination of newmaterials suggests new
names, we urge taxonomists to delay introduction of new names
until they have sampled sufficient material. Where name change
results from having to choose one of several names, maintaining
taxa that have similar medical attributes would serve medical my-
cology; such taxa should neither be so big as to hide medically
important phenotypic variation nor so small to lessen the distinc-
tion between genera and species. Where the names of medically
important fungi do change—and many will change as the new
code is applied—it may reflect the fact that medical mycology is
just one of many socially important activities that focus on fungi.
Good taxonomic studies do not always need new names immedi-
ately. For clinical routine, it is advocated to follow changes with
some delay, after validation by a convincing body of data, until a
sufficient degree of stability and consensus is reached.
At the species level, most changes concern subdivisions of clas-
sical phenotypic species, as new methods allow mycologists to
examine more and more of the genetic variation, including the
entire genomes of populations of fungi. As new research tech-
niques become widespread in clinics, clinicians also will be able to
recognize more species. Until, after clinical evaluation, newly dis-
covered species prove to be different in terms of patient manage-
ment, in daily clinical routine, it might be better to unite such
siblings as “species complexes.”
Researchers and clinicians should work together to achieve a
reasonable degree of nomenclatural stability during the decades
when large changes are unavoidable. Even when a disease caused
by two or more closely related species is treated by the same ther-
apy, insights into diversity of the speciesmay advancemedicine by
allowing clinicians to use this knowledge to discover previously
overlooked and consistent differences. Specialized websites are
available where diagnostic materials are provided as an aid for
identification and the best current taxonomy is available as mat-
ters change.
ACKNOWLEDGMENTS
The contents of this paper have been communicated to theNomenclature
Committee for Fungi (NCF) (www.ima-mycology.org/CFF): S. A. Red-
head, L. Norvell, and P. Kirk, and the International Commission on the
Taxonomy of Fungi (ICTF): K. A. Seifert and A. Miller.
The members of the ISHAM Working Group on Nomenclature of
Medical Fungi are Teun Boekhout (CBS-KNAW Fungal Biodiversity
Centre, Utrecht, The Netherlands, and Institute for Biodiversity and Eco-
system Dynamics, University of Amsterdam, Amsterdam, The Nether-
lands), Arunaloke Chakrabarti (Mycology Division, Department ofMed-
ical Microbiology, Postgraduate Institute of Medical Education and
Research [PGIMER], Chandigarh, India), AnuradhaChowdhary (Vallab-
hbhai Patel Chest Institute, Delhi, India), Garry Cole (Department of
Biology and South Texas Center for Emerging Infectious Diseases, Uni-
versity of Texas at San Antonio, San Antonio, TX), Olivier A. Cornely
(Department I of Internal Medicine, University Hospital, ZKS Köln,
BMBF 01KN1106, Cologne and Excellence Cluster on Cellular Stress Re-
sponses in Aging-Associated Diseases [CECAD], University of Cologne,
Cologne, Germany), Pedro W. Crous (CBS-KNAW Fungal Biodiversity
Centre, Utrecht, The Netherlands, and Institute for Biodiversity and Eco-
system Dynamics, University of Amsterdam, Amsterdam, The Nether-
lands), Christophe D’Enfert (Fungal Biology and Pathogenicity Unit, In-
stitut Pasteur, Paris, France), Dea Garcia-Hermoso (Institut Pasteur,
Unité de Mycologie Moléculaire, Centre National de Référence Mycoses
Invasives et Antifongiques, Paris, France), D. David Ellis (School of Mo-
lecular & Biomedical Science, The University of Adelaide, Adelaide, Aus-
tralia, and National Institute of Allergy and Infectious Diseases, NIH,
Bethesda, MD), Cornelia Lass-Flörl (Division of Hygiene and Medical
Commentary
1060 jcm.asm.org April 2015 Volume 53 Number 4Journal of Clinical Microbiology
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
Microbiology, Innsbruck Medical University, Innsbruck, Austria), Stuart
Levitz (Center of AIDS Research, University of Massachusetts Medical
School,Worcester,MA), Ruo-Yu Li (Research Center forMedicalMycol-
ogy, Peking University, Beijing, China), Aaron P. Mitchell (200B Mellon
Institute, Department of Biological Sciences, CarnegieMellonUniversity,
Pittsburgh, PA), KerryO’Donnell (Bacterial Foodborne Pathogens&My-
cology Research Unit, U.S. Department of Agriculture, Agriculture Re-
search Service, Peoria, IL), John R. Perfect (Department of Medicine,
Division of Infectious Diseases, Duke UniversityMycology Research Unit
[DUMRU], Durham, NC), Flavio Queiroz Telles (Division of Infectious
Diseases, Department of Public Health, Hospital de Clinicas, Universi-
dade Federal do Parana, Curitiba, Brazil), Deanna A. Sutton (Fungus
Testing Laboratory, Department of Pathology, School of Medicine, Uni-
versity of Texas Health Science Center at San Antonio, San Antonio, TX),
Kerstin Voigt (Microbial Resource Collection Friedrich-Schiller-Univer-
sität, Jena, Germany), Theodore C. White (School of Biological Sciences,
University of Missouri at Kansas City, Kansas City, MO), and Liyan Xi
(Department of Dermatology, Second Affiliated Hospital, Sun Yat-Sen
University, Guangzhou, China).
REFERENCES
1. Hawksworth DL, Crous PW, Redhead SA, Reynolds DR, Samson RA,
Seifert KA, Taylor JW, Wingfield MJ, Abaci O, Aime C, Asan A, Bai FY, de
Beer ZW, Begerow D, Berikten D, Boekhout T, Buchanan PK, Burgess T,
Buzina W, Cai L, Cannon PF, Crane JL, Damm U, Daniel HM, van
Diepeningen AD, Druzhinina I, Dyer PS, Eberhardt U, Fell JW, Frisvad JC,
Geiser DM, Geml J, Glienke C, Gräfenhan T, Groenewald JZ, Groenewald
M, de Gruyter J, Guého-Kellermann E, Guo LD, Hibbett DS, Hong SB, de
Hoog GS, Houbraken J, Huhndorf SM, Hyde KD, Ismail A, Johnston PR,
Kadaifciler DG, Kirk PM, Kõljalg U, Kurtzman CP, et al. 2011. The
Amsterdam Declaration on Fungal Nomenclature. IMA Fungus 2:105–112.
http://dx.doi.org/10.5598/imafungus.2011.02.01.14.
2. de Hoog GS, Guarro J, Gené J, Figueras MJ (ed). 1995. Atlas of clinical
fungi, 1st ed. Centraalbureau voor Schimmelcultures, Utrecht, The Neth-
erlands.
3. de Hoog GS, Guarro J, Gené J, Figueras MJ (ed). 2013. Atlas of clinical
fungi, 3A ed. CBS-KNAWFungal Biodiversity Centre, Utrecht, TheNeth-
erlands.
4. Schmalreck AF, Lackner M, Becker K, Fegeler W, Czaika V, Ulmer H,
Lass-Flörl C. 2014. Phylogenetic relationships matter: antifungal suscep-
tibility among clinically relevant yeasts. Antimicrob. Agents Chemother.
58:1575–1585. http://dx.doi.org/10.1128/AAC.01799-13.
5. Samson RA, Yilmaz N, Houbraken J, Spierenburg H, Seifert KA,
Peterson SW, Varga J, Frisvad JC. 2011. Phylogeny and nomenclature of
the genus Talaromyces and taxa accommodated in Penicillium subgenus
Biverticillium. Stud. Mycol. 70:159 –183. http://dx.doi.org/10.3114
/sim.2011.70.04.
6. Kwon-Chung KJ. 2012. Taxonomy of fungi causing mucormycosis and
entomophthoramycosis (zygomycosis) and nomenclature of the disease:
molecular mycologic perspectives. Clin. Infect. Dis. 54(Suppl 1):S8–S15.
http://dx.doi.org/10.1093/cid/cir781.
7. Hibbett SD, Ohman A, Kirk PM. 2009. Phenotypic variability: underly-
ingmechanisms and limits domatter.NewPhytol. 184:279–282. http://dx
.doi.org/10.1111/j.1469-8137.2009.03042.x.
8. O’Gorman CM, Fuller HT, Dyer PS. 2009. Discovery of a sexual cycle in
the opportunistic fungal pathogenAspergillus fumigatus. Nature 457:471–
474. http://dx.doi.org/10.1038/nature07528.
9. Houbraken J, Samson RA. 2011. Phylogeny of Penicillium and the segre-
gation of Trichocomaceae into three families. Stud Mycol. 70:1–51. http:
//dx.doi.org/10.3114/sim.2011.70.01.
10. Pitt JI, Taylor JW. 2014. Aspergillus, its sexual states and the new Inter-
national Code ofNomenclature.Mycologia. 106:1051–1062. http://dx.doi
.org/10.3852/14-060.
11. Sigler L, Sutton DA, Gibas CF, Summerbell RC, Noel RK, Iwen PC.
2010. Phialosimplex, a new anamorphic genus associated with infections
in dogs and having phylogenetic affinity to the Trichocomaceae. Med.
Mycol. 48:335–345. http://dx.doi.org/10.3109/13693780903225805.
12. Liti G, Carter DM, Moses AM, Warringer J, Parts L, James SA, Davey
RP, Roberts IN, Burt A, Koufopanou V, Tsai IJ, Bergman CM, Ben-
sasson D, O’Kelly MJ, van Oudenaarden A, Barton DB, Bailes E,
Nguyen AN, Jones M, Quail MA, Goodhead I, Smith F, Blomberg A,
Durbin R, Louis EJ. 2009. Population genomics of domestic and wild
yeasts. Nature 458:337–341. http://dx.doi.org/10.1038/nature07743.
13. Ellison CE, Hall C, Kowbel D, Welch J, Brem RB, Glass NL, Taylor JW.
2011. Population genomics and local adaptation inwild isolates of amodel
microbial eukaryote. Proc. Natl. Acad. Sci. U. S. A. 108:2831–2836. http:
//dx.doi.org/10.1073/pnas.1014971108.
14. Neafsey DE, Barker BM, Sharpton TJ, Stajich JE, Park DJ, Whiston E,
Hung CY, McMahan C, White J, Sykes S, Heiman D, Young S, Zeng Q,
Abouelleil A, Aftuck L, Bessette D, Brown A, FitzGerald M, Lui A,
Macdonald JP, Priest M, Orbach MJ, Galgiani JN, Kirkland TN, Cole
GT, Birren BW, Henn MR, Taylor JW, Rounsley SD. 2010. Population
genomic sequencing ofCoccidioides fungi reveals recent hybridization and
transposon control. Genome Res. 20:938–946. http://dx.doi.org/10.1101
/gr.103911.109.
15. Oliveira MM, Almeida-Paes R, Muniz MM, Gutierrez-Galhardo MC, Zan-
cope-Oliviera RM. 2011. Phenotypic and molecular identification of Sporo-
thrix isolates from an epidemic area of sporotrichosis in Brazil. Myco-
pathologia 172:257–267. http://dx.doi.org/10.1007/s11046-011-9437-3.
16. Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I,
Klaassen CH, Meis JF. 2012. Species-specific antifungal susceptibility
patterns of Scedosporium and Pseudallescheria. Antimicrob. Agents Che-
mother. 56:2635–2642. http://dx.doi.org/10.1128/AAC.05910-11.
17. Turner E, Jacobson DJ, Taylor JW. 2011. Genetic architecture of a
reinforced, postmating, reproductive isolation barrier between Neuro-
spora species indicates evolution via natural selection. PLoS Genet.
7:e1002204. http://dx.doi.org/10.1371/journal.pgen.1002204.
18. Perrone G, Stea G, Epifani F, Varga J, Frisvad JC, Samson RA. 2011.
Aspergillus niger contains the cryptic phylogenetic species A. awamori.
Fungal Biol. 115:1138–1150. http://dx.doi.org/10.1016/j.funbio.2011.07
.008.
19. Varga J, Frisvad JC, Kocsubé S, Brankovics B, Tóth B, Szigeti G,
Samson RA. 2011. New and revisited species in Aspergillus section Nigri.
Stud. Mycol. 69:1–17. http://dx.doi.org/10.3114/sim.2011.69.01.
20. Bensch K, Braun U, Groenewald JZ, Crous PW. 2012. The genus Cla-
dosporium. Stud. Mycol. 72:1–401. http://dx.doi.org/10.3114/sim0003.
21. Sarver BAJ, Ward TJ, Gale LR, Broz K, Kistler HC, Aoki T, Nicholson
P, Carter J, O’Donnell K. 2011. Novel Fusarium head blight pathogens
from Nepal and Louisiana revealed by multilocus genealogical concor-
dance. Fungal Genet. Biol. 48:1096–1107. http://dx.doi.org/10.1016/j.fgb
.2011.09.002.
Continued next page
Commentary
April 2015 Volume 53 Number 4 jcm.asm.org 1061Journal of Clinical Microbiology
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
Sybren de Hoog (born 1948) is group leader of
Medical Fungi at the CBS-KNAW Fungal Bio-
diversity Centre at Utrecht, The Netherlands.
He also holds professorships at universities in
The Netherlands, Brazil, China, and Saudi Ara-
bia. Areas of interest are ecology and evolution
of pathogenic fungi, on which he has written
over 550 refereed papers. He is the leading au-
thor of theAtlas of Clinical Fungi. Dr. deHoog is
past-President of the International Society for
Human and Animal Mycology (ISHAM). In
this function, he assisted in the organization of ISHAMand satellite congress
in Tokyo, Japan, and Beijing, China, in 2009, and he was program chairman
of the TIMM congress in Amsterdam, The Netherlands. His teaching activ-
ities include the CBS Course Medical Mycology for hospital personnel,
which is given regularly in several European and Asian countries.
Commentary
1062 jcm.asm.org April 2015 Volume 53 Number 4Journal of Clinical Microbiology
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
